Author

J. Leslie

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

F. Oakley· 3 shared D. Geh· 2 shared E. Ramon-Gil· 2 shared H. Paish· 2 shared J. Mann· 2 shared L. Borthwick· 2 shared A. Buskin· 1 shared A. Collins· 1 shared

Activity by Year

2018-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCell Biology

F. Oakley

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

ST3Gal1 synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer

R. Garnham, D. Geh, R. Nelson, E. Ramon-Gil, L. Wilson, E. N. Schmidt, L. Walker, B. Adamson, A. Buskin, A. Hepburn, K. Hodgson, H. Kendall, F. M. Frame, N. J. Maitland, K. Coffey, , E. Scott

This study shows ST3Gal1 promotes immune evasion in prostate cancer by synthesizing Siglec ligands, and its activity can be modulated by enzalutamide.

bioRxiv · Apr 3, 2023 · PreprintCancer Biology

CXCR2 inhibition enables NASH-HCC immunotherapy

J. Leslie, J. B. G. Mackey, T. Jamieson, E. Ramon-Gil, T. M. Drake, F. Fercoq, W. Clark, K. Gilroy, A. Hedley, C. Nixon, S. Luli, M. Laszczewska, R. Pinyol, R. Esteban-Fabro, C. E. Willoughby, , Carlin

This study shows that combining CXCR2 inhibition with anti-PD1 therapy enhances immunotherapy response in NASH-HCC by reprogramming tumor-associated neutrophils.

bioRxiv · Feb 24, 2022Cancer Biology

mTORC1-Plin3 pathway is essential to activate lipophagy and protects against hepatosteatosis.

M. Garcia-Macia, A. Santos-Ledo, J. Leslie, H. Paish, A. Watson, L. Borthwick, J. Mann, F. Oakley, V. I. Korolchuk, D. A. Mann

This study identifies the mTORC1-Plin3 pathway as essential for lipophagy, which protects against hepatosteatosis by promoting lipid droplet degradation.

bioRxiv · Oct 21, 2019Cell Biology

Loss of ELK1 has differential effects on age-dependent organ fibrosis and integrin expression

J. T. Cairns, A. Habgood, R. Edwards-Pritchard, C. Wilkinson, I. D. Stewart, J. Leslie, B. C. Blaxall, K. Susztak, S. Alberti, A. Nordheim, F. Oakley, R. G. Jenkins, A. L. Tatler

This study shows that loss of ELK1 leads to age-related fibrosis in the lung and liver but not heart or kidneys, and links reduced ELK1 to cigarette smoke exposure.

bioRxiv · Sep 5, 2019Pathology

A novel bioreactor technology for modelling fibrosis in human and rodent precision-cut liver slices.

H. Paish, L. Reed, H. Brown, M. Bryan, O. Govaere, J. Leslie, B. Barksby, J. French, S. White, D. Manas, S. Robinson, G. Spoletini, C. Griffiths, D. Mann, L. Borthwick, , F. Oakley

This paper develops a bioreactor system that extends the viability of precision-cut liver slices (PCLS) to 6 days under normoxic conditions and demonstrates its use in modeling fibrogenesis and testing anti-fibrotic drugs.

bioRxiv · May 25, 2018Cell Biology